Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

被引：0

作者：

Shukui Qin

Jin Li

Haijun Zhong

Chuan Jin

Lili Chen

Xianglin Yuan

Qingxia Fan

Kehe Chen

Peiguo Cao

Jianjun Xiao

Da Jiang

Tao Zhang

Hongyu Zhang

Xicheng Wang

Wei Wang

Lin Han

Qingyu Wang

Jun Zhu

机构：

[1] Eastern Theater General Hospital of PLA China,Department of Oncology, Qinhuai Medical Area

[2] Tongji University Shanghai East Hospital,Department of Oncology

[3] Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Department of Abdominal Oncology

[4] Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Department of Oncology

[5] Taizhou First People’s Hospital,Department of Hematology and Oncology

[6] Tongji Hospital,Department of Oncology

[7] Huazhong University of Science and Technology,Department of Oncology

[8] The First Affiliated Hospital of Zhengzhou University,Department of Oncology

[9] The People’s Hospital of Guangxi Zhuang Autonomous Region,Department of Oncology

[10] The Third Xiangya Hospital of Central South University,Chemotherapeutic Department

[11] Zhongshan City People’s Hospital,Department of Oncology

[12] The Fourth Hospital of Hebei Medical University,Department of Oncology

[13] The First Affiliated Hospital of Chongqing Medical University,Cancer Center

[14] The Fifth Affiliated Hospital Sun Yat-sen University,Department of Oncology

[15] The First Affiliated Hospital of Guangdong Pharmaceutical University,Department of Gastrointestinal Oncology

[16] The First People’s Hospital of Foshan,undefined

[17] Shanghai Henlius Biotech,undefined

[18] Inc.,undefined

来源：

British Journal of Cancer | 2022年 / 127卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2249 / 2249

共 50 条

[1] Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
Qin, Shukui
Li, Jin
Zhong, Haijun
Jin, Chuan
Chen, Lili
Yuan, Xianglin
Fan, Qingxia
Chen, Kehe
Cao, Peiguo
Xiao, Jianjun
Jiang, Da
Zhang, Tao
Zhang, Hongyu
Wang, Xicheng
Wang, Wei
Han, Lin
Wang, Qingyu
Zhu, Jun
BRITISH JOURNAL OF CANCER, 2022, 127 (12) : 2241 - 2248
[2] Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial
Ren, Chao
Mai, Zong-Jiong
Jin, Ying
He, Ming-Ming
Wang, Zhi-Qiang
Luo, Hui-Yan
Zhang, Dong-Sheng
Wu, Chen-Yi
Wang, Feng
Xu, Rui-Hua
AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2946 - +
[3] Anti-PD-1 antibody therapy for epithelial skin malignancies An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
Ishii, Maki
Hirai, Ikuko
Tanese, Keiji
Fusumae, Takayuki
Nakamura, Yoshio
Fukuda, Keitaro
Uchi, Hiroshi
Kabashima, Kenji
Otsuka, Atsushi
Yokota, Kenji
Yamazaki, Naoya
Namikawa, Kenjiro
Fujimura, Taku
Takenouchi, Tatsuya
Yamamoto, Yuki
Nishiguchi, Mana
Sato, Yasunori
Amagai, Masayuki
Funakoshi, Takeru
MEDICINE, 2020, 99 (44) : E22913
[4] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
Huang, X.
Shen, J.
Xiong, Y.
Wang, Y.
Cao, X.
He, M.
Zou, G.
Deng, Y.
Wang, X.
Lan, C.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
[5] Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial
Jiang, Y-F.
Bei, W-X.
Wang, L.
Xu, C.
Lu, N.
Liang, H.
Ke, L-R.
Ye, Y-F.
Fang, T.
He, S.
Dong, S-H.
Liu, Q.
Zhang, C.
Xia, W.
Zhao, C.
Xie, C.
Liu, G.
Xiang, Y-Q.
ANNALS OF ONCOLOGY, 2024, 35 : S633 - S634
[6] Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.
Wu, Xiaohua
Xia, Lingfang
Zhou, Qi
Zhu, Jianqing
Wang, Ke
Chen, Jie
Huang, Yi
Kurb, Gulina
Chang, Baoping
Zhao, Weidong
Wang, Xia
Yang, Yingjie
Lin, Zhongqiu
Luo, Xiaoyong
Lou, Ge
Wang, Chunyan
Wang, Jing
Meng, Haijin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
Cao, Yanshuo
Lu, Ming
Sun, Yu
Gong, Jifang
Li, Jie
Lu, Zhihao
Li, Jian
Zhang, Xiaotian
Li, Yan
Peng, Zhi
Zhou, Jun
Wang, Xicheng
Shen, Lin
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 779 - 789
[8] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
Yanshuo Cao
Ming Lu
Yu Sun
Jifang Gong
Jie Li
Zhihao Lu
Jian Li
Xiaotian Zhang
Yan Li
Zhi Peng
Jun Zhou
Xicheng Wang
Lin Shen
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 779 - 789
[9] CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial
Saunders, M. P.
Graham, J.
Cunningham, D.
Plummer, R.
Church, D.
Kerr, R.
Cook, S.
Zheng, S.
La Thangue, N.
Kerr, D.
ESMO OPEN, 2022, 7 (06)
[10] Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.
Qin, Shukui
Li, Jin
Zhong, Haijun
Jin, Chuan
Chen, Lili
Yuan, Xianglin
Fan, Qingxia
Chen, Kehe
Cao, Peiguo
Xiao, Jianjun
Jiang, Da
Zhang, Tao
Zhang, Hongyu
Wang, Xicheng
Wang, Wei
Wang, Qingyu
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →